FY2025 EPS Estimates for CMPS Boosted by Cantor Fitzgerald

COMPASS Pathways plc (NASDAQ:CMPS - Free Report) - Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for COMPASS Pathways in a report released on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($1.91) per share for the year, up from their prior forecast of ($2.00). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share.

A number of other research firms have also commented on CMPS. HC Wainwright restated a "buy" rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Monday. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They set a "buy" rating and a $11.00 price target for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Finally, Canaccord Genuity Group lowered their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, February 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways has a consensus rating of "Buy" and a consensus target price of $20.20.

COMPASS Pathways Price Performance

NASDAQ:CMPS opened at $3.90 on Wednesday. COMPASS Pathways has a 52 week low of $2.49 and a 52 week high of $8.54. The firm's 50-day simple moving average is $3.34 and its 200 day simple moving average is $3.99. The firm has a market cap of $362.12 million, a price-to-earnings ratio of -1.77 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.03.

Institutional Trading of COMPASS Pathways

Several hedge funds have recently modified their holdings of the stock. Affinity Asset Advisors LLC boosted its position in shares of COMPASS Pathways by 183.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 850,512 shares of the company's stock worth $3,215,000 after purchasing an additional 550,000 shares in the last quarter. Barclays PLC grew its stake in COMPASS Pathways by 2.1% in the 4th quarter. Barclays PLC now owns 419,194 shares of the company's stock valued at $1,585,000 after purchasing an additional 8,718 shares during the period. Geode Capital Management LLC grew its position in COMPASS Pathways by 160.3% during the third quarter. Geode Capital Management LLC now owns 42,169 shares of the company's stock valued at $266,000 after buying an additional 25,970 shares during the period. Hennion & Walsh Asset Management Inc. increased its stake in shares of COMPASS Pathways by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company's stock worth $661,000 after purchasing an additional 26,787 shares during the last quarter. Finally, Altium Capital Management LLC purchased a new stake in COMPASS Pathways in the fourth quarter worth $5,384,000. Institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.